Outset Medical (NASDAQ:OM) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Outset Medical (NASDAQ:OM) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Other equities analysts have also issued research reports about the stock. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $7.00 target price on shares of Outset Medical in a research report on Wednesday, December 17th. Stifel Nicolaus dropped their price target on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. Finally, BTIG Research decreased their price objective on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Outset Medical presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Outset Medical Trading Up 1.1%

NASDAQ:OM opened at $3.56 on Friday. The stock has a market cap of $65.18 million, a price-to-earnings ratio of -0.52 and a beta of 2.12. The company has a debt-to-equity ratio of 0.76, a quick ratio of 5.40 and a current ratio of 6.67. Outset Medical has a 1 year low of $3.00 and a 1 year high of $21.98. The business has a fifty day moving average of $3.98 and a 200-day moving average of $7.18.

Insider Buying and Selling at Outset Medical

In other news, CEO Leslie Trigg sold 11,794 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $60,385.28. Following the completion of the sale, the chief executive officer owned 107,823 shares in the company, valued at approximately $552,053.76. This represents a 9.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marc Nash sold 5,375 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $27,520.00. Following the sale, the executive vice president directly owned 42,785 shares of the company’s stock, valued at approximately $219,059.20. This represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 40,910 shares of company stock valued at $193,040. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Outset Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. acquired a new stake in shares of Outset Medical during the third quarter valued at approximately $5,324,000. Geode Capital Management LLC lifted its position in shares of Outset Medical by 955.9% in the 2nd quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after acquiring an additional 376,196 shares in the last quarter. Pura Vida Investments LLC boosted its stake in Outset Medical by 8,482.4% in the 2nd quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after purchasing an additional 424,120 shares during the period. R Squared Ltd purchased a new position in Outset Medical during the 3rd quarter worth approximately $146,000. Finally, Federated Hermes Inc. grew its position in Outset Medical by 44,416.7% during the 3rd quarter. Federated Hermes Inc. now owns 72,117 shares of the company’s stock worth $1,018,000 after purchasing an additional 71,955 shares in the last quarter.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.